The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy

Expert Review of Anticancer Therapy

Volumn 16, Issue 7, 2016, Pages 697-703

  Passero, Frank C ^a   Grapsa, Dimitra ^b   Syrigos, Kostas N ^b   Saif, Muhammad Wasif ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Gemcitabine; Irinotecan liposome injection; MM 398; Nanoliposomal irinotecan; Pancreatic cancer

Indexed keywords

DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; IRINOTECAN SUCROSOFATE; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; LIPOSOME;

ANEMIA; ARTICLE; DECREASED APPETITE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG WITHDRAWAL; ENCAPSULATION; ENTEROCOLITIS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPOKALEMIA; LEUKOPENIA; LUNG EMBOLISM; METASTATIC PANCREATIC CANCER; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SEPTIC SHOCK; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE FREE SURVIVAL; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; LIPOSOMES; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84976293998     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1080/14737140.2016.1192471     Document Type: Article

References (40)

1. R.L.Siegel, K.D.Miller, A.Jemal Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan;66(1):7–30.
2. L.A.Torre, F.Bray, R.L.Siegel, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.
3. H.A.Burris3rd, M.J.Moore, J.Andersen, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403–2413.
4. T.Conroy, F.Desseigne, M.Ychou, et al.; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817–1825.• Phase III randomized trial demonstrating the superior efficacy of FOLFIRINOX versus single-agent gemcitabine for first-line treatment of metastatic pancreatic cancer.
5. D.D.Von Hoff, T.Ervin, F.P.Arena, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691–1703.• Phase III randomized trial demonstrating the superior efficacy of gemcitabine/nab-paclitaxel versus single-agent gemcitabine for first-line treatment of metastatic pancreatic cancer.
6. U.Pelzer, I.Schwaner, J.Stieler, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676–1681.•• First phase III study that demonstrated efficacy for second-line treatment of pancreatic cancer over best supportive care for pancreatic cancer that progressed on first-line therapy.
7. H.Oettle, H.Riess, J.M.Stieler, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423–2429.• Phase III trial establishing the efficacy of the OFF regimen compared to folinic acid and fluorouracil in patients with pancreatic cancer previously treated with gemcitabine-based therapy.
8. A.H.Ko, M.A.Tempero, Y.-S.Shan, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20;109(4):920–925.•• The first clinical trial studying the efficacy and toxicity of MM-398 in patients with gemcitabine-refractory metastatic pancreatic cancer.
9. A.C.Roy, S.R.Park, D.Cunningham, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567–1573.
10. B.Chibaudel, F.Maindrault-Gœbel, J.-B.Bachet, et al. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med. 2016 Apr;5(4):676–683.
11. A.Wang-Gillam, C.-P.Li, G.Bodoky, et al.; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545–557.•• Phase III randomized trial leading to FDA approval of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with pancreatic cancer previously treated with gemcitabine-based therapy.
12. FDA approves new treatment for advanced pancreatic cancer [cited 2016 Mar22]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468654.htm
13. Onivyde [package insert]. Merrimack Pharmaceuticals, Inc. 2015 Oct [cited 2016 Mar 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf
14. T.J.Smith, K.Bohlke, G.H.Lyman, et al.; American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199–3212.
15. D.C.Drummond, C.O.Noble, Z.Guo, et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271–3277.•• First description of the chemical structure and pharmacokinetics of nanoliposomal irinotecan.
16. A.V.Kalra, J.Kim, S.G.Klinz, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74:7003–7013.
17. T.C.Chang, H.S.Shiah, C.H.Yang, et al. Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015;75:579–586.•• The first-in-human clinical trial investigating the pharmacokinetics of nanoliposomal irinotecan.
18. M.A.Phelps, A.Sparreboom. Irinotecan pharmacogenetics: a finished puzzle?. J Clin Oncol. 2014;32:2287–2289.
19. E.De Mattia, E.Cecchin, G.Toffoli. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy. Drug Resist Updat. 2015;20:39–70.
20. F.A.De Jong, R.H.Mathijssen, R.Xie, et al. Flat-fixed dosing of irinotecan influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res. 2004;10:4068–4071.
21. F.Innocenti, R.L.Schilsky, J.Ramírez, et al. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014;32:2328–2334.
22. G.Toffoli, E.Cecchin, G.Corona, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061–3068.
23. X.Cai, W.Cao, H.Ding, et al. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai. J Cancer Res Clin Oncol. 2013;139:1579–1589.
24. X.Liu, D.Cheng, Q.Kuang, et al. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenom J. 2014;14:120–129.
25. C.-Y.Lu, C.-W.Huang, I.-C.Wu, et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting. Transl Oncol. 2015;8:474–479.
26. Y.Miyata, T.Touyama, T.Kusumi, et al. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. Int J Clin Oncol. 2015 Dec 28. [Epub ahead of print].
27. E.Beutler, T.Gelbart, A.Demina. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95:8170–8174.
28. S.Chen, L.Villeneuve, D.Jonker, et al. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genom. 2015;25:573–583.
29. E.Rouits, M.Boisdron-Celle, A.Dumont, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res. 2004 Aug 1;10(15):5151–5159.
30. S.Chen, I.Laverdiere, A.Tourancheau, et al. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. Pharmacogenomics. 2015;15:513–520.
31. L.Cortejoso, M.I.García, P.García-Alfonso, et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol. 2013;71:1463–1472.
32. B.Glimelius, H.Garmo, Å.Berglund, et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics. 2011;11:61–71.
33. D.Iusuf, M.Ludwig, A.Elbatsh, et al. OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol Cancer Ther. 2014;13:492–503.
34. J.-Y.Han, H.-S.Lim, E.S.Shin, et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol. 2006 May 20;24(15):2237–2244.
35. S.R.Jada, R.Lim, C.I.Wong, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci. 2007 Sep;98(9):1461–1467.
36. M.Onoue, T.Terada, M.Kobayashi, et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol. 2009 Apr;14(2):136–142.
37. L.Cheng, M.Li, J.Hu, et al. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol. 2014;73:551–560.
38. K.Araki, K.Fujita, Y.Ando, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 2006;97:1255–1259.
39. H.Minami, K.Sai, M.Saeki, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom. 2007;17:497–504.
40. W.W.Ma, I.Chung, I.Lang, et al. Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors. J Clin Oncol. 2015;33(suppl):abstr e13588.